Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 21:68:102423.
doi: 10.1016/j.eclinm.2024.102423. eCollection 2024 Feb.

Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study

Collaborators, Affiliations

Prevalence of chronic cough, its risk factors and population attributable risk in the Burden of Obstructive Lung Disease (BOLD) study: a multinational cross-sectional study

Hazim Abozid et al. EClinicalMedicine. .

Abstract

Background: Chronic cough is a common respiratory symptom with an impact on daily activities and quality of life. Global prevalence data are scarce and derive mainly from European and Asian countries and studies with outcomes other than chronic cough. In this study, we aimed to estimate the prevalence of chronic cough across a large number of study sites as well as to identify its main risk factors using a standardised protocol and definition.

Methods: We analysed cross-sectional data from 33,983 adults (≥40 years), recruited between Jan 2, 2003 and Dec 26, 2016, in 41 sites (34 countries) from the Burden of Obstructive Lung Disease (BOLD) study. We estimated the prevalence of chronic cough for each site accounting for sampling design. To identify risk factors, we conducted multivariable logistic regression analysis within each site and then pooled estimates using random-effects meta-analysis. We also calculated the population attributable risk (PAR) associated with each of the identifed risk factors.

Findings: The prevalence of chronic cough varied from 3% in India (rural Pune) to 24% in the United States of America (Lexington,KY). Chronic cough was more common among females, both current and passive smokers, those working in a dusty job, those with a history of tuberculosis, those who were obese, those with a low level of education and those with hypertension or airflow limitation. The most influential risk factors were current smoking and working in a dusty job.

Interpretation: Our findings suggested that the prevalence of chronic cough varies widely across sites in different world regions. Cigarette smoking and exposure to dust in the workplace are its major risk factors.

Funding: Wellcome Trust.

Keywords: Chronic cough; Epidemiology; Excess risk; Global health.

PubMed Disclaimer

Conflict of interest statement

Fatima Rodrigues declares grants and personal fees from A. Menarini, Boehringer Ingelheim, Teva Pharma, Novartis, GlaxoSmithKline, AstraZeneca, VitalAire and Nippon Gases outside the submitted work. Wan C. Tan received grants from the Canadian Institute of Heath Research (CIHR/Rx&D Collaborative Research Program Operating Grants- 93,326) with industry partners Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., Nycomed Canada Inc., Pfizer Canada Ltd. for conducting the longitudinal population-based Canadian Cohort of Obstructive Lung Disease (CanCOLD) study on COPD. David Mannino is a consultant to GSK, AstraZeneca, Regeneron, Genentech, COPD Foundation, and expert witness on behalf of people suing Tobacco Industry (Schlesinger Law Firm). Sonia Buist is Chair of the Data Safety & Monitoring Board for the RELIANCE Clinical Trial. Frits Franssen declares personal fees from AstraZeneca, Chiesi, GlaxoSmithKline, MSD, Pieris, and Verona Pharma. Robab Breyer-Kohansal declares consulting fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Novartis Pharma, and Sanofi, and participation on advisory boards for AstraZeneca, Menarini, and Sanofi. Thorarinn Gislason received a grant from the Icelandic Research Fund. Kevin Mortimer declares participation on advisory boards for AstraZeneca and GlaxoSmithKline. Sylvia Hartl declares grants from GSK, Chiesi Farma, Menarini Pharma, and AstraZeneca, and participation on advisory boards for Menarini Pharma and GSK. AFSA declares a grant from the COLT Foundation (CF/01/21).

Figures

Fig. 1
Fig. 1
Prevalence of chronic cough across 41 sites of the BOLD study, by gross national income.
Fig. 2
Fig. 2
Population Attributable Risk for chronic cough (i.e., prevalence of chronic cough attributable to different risk factors) by BOLD study site. Each risk factor is represented by a different colour: red, current smoking; pink, passive smoking; grey, dusty job; light blue, obesity; green, education; brown, tuberculosis; yellow, hypertension; dark blue, FEV1/FVC < LLN; and white, unexplained.

References

    1. Magni C., Chellini E., Zanasi A. Cough variant asthma and atopic cough. Multidiscip Respir Med. 2010;5:99–103. - PMC - PubMed
    1. Chamberlain S.A.F., Garrod R., Douiri A., et al. The impact of chronic cough: a cross-sectional European survey. Lung. 2015;193:401–408. - PubMed
    1. Kang M.-G., Song W.-J., Kim H.-J., et al. Point prevalence and epidemiological characteristics of chronic cough in the general adult population: the Korean National Health and Nutrition Examination Survey 2010-2012. Medicine (Baltimore) 2017;96 - PMC - PubMed
    1. Huang K., Gu X., Yang T., et al. Prevalence and burden of chronic cough in China: a national cross-sectional study. ERJ Open Res. 2022;8 - PMC - PubMed
    1. Arinze J.T., Hofman A., de Roos E.W., et al. The interrelationship of chronic cough and depression: a prospective population-based study. ERJ Open Res. 2022;8:69–2022. - PMC - PubMed